Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Non-Hodgkin

Explore clinical trials studying Lymphoma, Non-Hodgkin. Study availability and eligibility vary by location and protocol.

2,774 public trials 698 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Non-Hodgkin trial results

Completed

A Multiple Dose Opioid Challenge Study

NCT02611752

Conditions
Chemically-Induced Disorders, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Vince and Associates Clinical Research Overland Park, Kansas, United States
  • University of Kentucky Lexington, Kentucky, United States
  • New York Psychiatric Institute New York, United States
View Trial Details
Completed

Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)

NCT01007448

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Florida Academic Dermatology Centers Miami, Florida, United States
  • Emory University Atlanta, Georgia, United States
  • Rush University Chicago, Illinois, United States
View all 17 locations
View Trial Details
Completed

A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma

NCT01169298

Conditions
Adult T-Cell Leukemia-Lymphoma, Hematologic Diseases, Hemic and Lymphatic Diseases, +15 more
Locations
  • National Kyusyu Cancer Center Fukuoka, Japan
  • Imamura Bun-in Hospital Kagoshima, Japan
  • Kumamoto University Hospital Kumamoto, Japan
  • Nagasaki University Hospital Nagasaki, Japan
View Trial Details
Completed

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

NCT00106431

Conditions
Cutaneous T-Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • UCLA Jonsson Cancer Center Los Angeles, California, United States
  • Stanford Comprehensive Cancer Center Stanford, California, United States
  • Boston Medical Center Boston, Massachusetts, United States
  • University of Pennsylvania Abrahamson Cancer Center Philadelphia, Pennsylvania, United States
View Trial Details
Completed

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

NCT03357471

Conditions
Active Ankylosing Spondylitis, Active Psoriatic Arthritis, Hemic and Lymphatic Diseases, +11 more
Locations
  • Ra0098 116 Mesa, Arizona, United States
  • Ra0098 107 Mesa, Arizona, United States
  • Ra0098 135 Phoenix, Arizona, United States
  • Ra0098 119 Tucson, Arizona, United States
View all 22 locations
View Trial Details

Related conditions